There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AstraZeneca (AZN – Research Report) and Context Therapeutics (CNTX – Research Report) with bullish sentiments.
AstraZeneca (AZN)
In a report released today, Steve Scala from TD Cowen reiterated a Buy rating on AstraZeneca, with a price target of $86.00. The company’s shares closed last Tuesday at $64.52.
According to TipRanks.com, Scala is a 5-star analyst with an average return of
Currently, the analyst consensus on AstraZeneca is a Strong Buy with an average price target of $84.25, representing a 33.1% upside. In a report issued on October 13, BMO Capital also assigned a Buy rating to the stock with a $83.00 price target.
See the top stocks recommended by analysts >>
Context Therapeutics (CNTX)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Context Therapeutics, with a price target of $4.00. The company’s shares closed last Tuesday at $1.32.
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of
Context Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AZN:
- AstraZeneca to hold a virtual meeting
- AstraZeneca: Enhertu demonstrated meaningful survival in Phase II trial
- AstraZeneca says Dato-DXd improved progression-free survival in NSCLC trial
- AstraZeneca reports ‘positive’ results from TROPION-Breast01 Phase III trial
- AstraZeneca, Daiichi Sankyo’s Enhertu approved in EU for certain NSCLC
